Elusive Neurotoxicity in T Cell-Boosting Anticancer Therapies. Issue 4 (April 2019)

• Record Type: Journal Article
• Authors: Zheng, Ping-Pin; Kros, Johan M.; Wang, Guanyu
• Is Part Of: Trends in immunology. Volume 40:Issue 4(2019)
• Page Start: 274
• Page End: 278
• Publication Date: 2019-04
• Subjects: neurotoxicity -- T cell-boosting therapies -- CAR-T -- BiTEs -- encephalopathy -- CNS damage; Immunology -- Periodicals; 571.96
• DOI: 10.1016/j.it.2019.02.005
• Languages: English
• ISSNs: 1471-4906

Abstract

Abstract : Several T cell-boosting anticancer therapies (including anti-CD19 CAR-T cells and bi-specific T cell engagers, BiTEs) have been approved by the FDA for specific clinical indications. Their potency has been demonstrated in various clinical trials, but some life-threatening complications such as neurotoxicity remain poorly understood. Thus, by conducting multifaceted investigations, a better understanding of T cell immunotherapy-associated neurotoxicity to bridge the gap between basic research and clinical practice is urgently needed.